According to previous studies, EGF reduces the palmitoylation of CUB domain-containing protein 1 (CDCP1) and inhibits the palmitoylation-dependent degradation of CDCP1 to promote its expression on the cell surface of ovarian cancer cells [36,37]. Here, EGF is linked to ovarian cancer.